Physiogenex is a renowned preclinical contract research organization (CRO) specializing in metabolic and cardiovascular diseases.
In this focused niche market we provide integrated preclinical and scientific consultancy services to optimize drug discovery development and shorten the time to market for new targets and compounds. Our in-house capabilities and innovative customized solutions, combined with our scientific team expertise, provide our partners with reliable and long-lasting R&D collaborations.
We offer the following services :
Physiogenex pioneers the development of radiolabeled tracer-based kinetic methods and predictive animal nutritional models. We thus provide our partners with pertinent and reliable discovery and preclinical data forsuccessful strategic decision-making. Physiogenex has rapidly achieved global player status by virtue of its unique expertise, covering complex metabolic disorders associated with diabetes, obesity, lipid disorders (dyslipidemia, hypercholesterolemia) and liver disorders ( NAFLD / NASH), hypertension and cardiovascular diseases.
Physiogenex is an entrepreneurial, science-driven company dedicated to helping pharmaceutical, biotechnology and nutraceutical companies.
In vivo pharmacology studies based on diet-induced & predictive animal models combined to state of the art experiments in rodents.
- Glucose uptake
- Free fatty acid oxidation
Physiogenex SAS has not received any reviews.
Physiogenex SAS has not received any endorsements.